Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil

Colorectal Cancer Clinical Trial

Official title:

A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan & Ciclosporin in COLOrectal Cancer Therapy (PICCOLO)]

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00389870
• Other study ID #: CDR0000510284
• Secondary ID: CTRU-PICCOLO-MO-
• Status: Completed
• Phase: Phase 3
• Start date: December 2006

Study information

• Verified date: May 2022
• Source: University of Leeds
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cyclosporine may help irinotecan work better by making tumor cells more sensitive to the drug. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Panitumumab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether irinotecan is more effective when given with or without panitumumab or cyclosporine in treating colorectal cancer.

PURPOSE: This randomized phase III trial is studying irinotecan to compare how well it works when given with or without panitumumab or cyclosporine in treating patients with advanced or metastatic colorectal cancer that did not respond to fluorouracil.

Description:

OBJECTIVES:

Primary

• Compare the efficacy and toxicity of single-agent irinotecan hydrochloride (Ir) vs Ir with cyclosporine (IrC) in patients with fluorouracil-resistant advanced colorectal cancer.

• Compare the efficacy of single-agent Ir vs Ir with panitumumab (IrP) in these patients.

Secondary

• Correlate the toxicity of Ir and/or IrC with genetic variability in the enzymes involved in irinotecan hydrochloride's disposition pathway.

• Compare IrC to Ir and its metabolites (SN38; SN38G), in terms of pharmacokinetic profile.

• Correlate the benefit of IrP with tumor expression of epidermal growth factor receptor (EGFR) or its known down-stream molecules as a predictive measure.

• Correlate IrP efficacy or toxicity (specifically the severity of skin rash) with somatic alterations in the EGFR gene and/or with germline variability in related genes.

OUTLINE: This is a randomized, open-label, controlled, multicenter study. Patients are stratified according to prior cetuximab (yes vs no). Patients are randomized to 1 of 3 treatment arms.

• Arm I: Patients receive irinotecan hydrochloride IV over 30-90 minutes on day 1.

• Arm II: Patients receive irinotecan hydrochloride IV over 15-40 minutes on day 1 and oral cyclosporine three times a day on days 1-3.

• Arm III: Patients receive panitumumab IV over 30-90 minutes followed by irinotecan hydrochloride IV over 30-90 minutes on day 1. Single-agent panitumumab may be continued during breaks in chemotherapy treatment.

In all arms, treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue treatment in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline and at 12 and 24 weeks.

After completion of study treatment, patients are followed every 12 weeks for 1 year.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 1,269 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1198
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of colorectal adenocarcinoma meeting 1 of the following criteria:

• Previous or current histologically confirmed primary adenocarcinoma of the colon or rectum and clinical/radiological evidence of advanced or metastatic disease

• Histologically or cytologically confirmed metastatic adenocarcinoma with clinical or radiological evidence of colorectal primary tumor

• Unidimensionally measurable disease

• Disease progression during or after prior fluorouracil with or without oxaliplatin therapy and/or with or without bevacizumab

• Adjuvant therapy and/or prior therapy for advanced disease allowed

• No clinical or radiological evidence of pleural effusion or ascites causing = grade 2 dyspnea

• No clinical or radiological evidence of biliary obstruction

• No known CNS metastases or carcinomatous meningitis

PATIENT CHARACTERISTICS:

• WHO performance status 0-2

• Life expectancy = 12 weeks

• Hemoglobin > 10.0 g/dL

• WBC > 3,000/mm³

• Platelet count > 100,000/mm³

• Glomerular filtration rate > 50 mL/min OR EDTA clearance > 60 mL/min

• Bilirubin < 1.46 mg/dL

• Alkaline phosphatase = 5 times upper limit of normal (ULN)

• AST and ALT = 2.5 times ULN

• No history of Gilbert's syndrome

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 6 months after completion of study treatment

• Capable of completing quality of life questionnaires

• No prior anaphylactic allergic reaction to cetuximab

• No other prior or concurrent cancer (excluding nonmelanomatous skin cancer)

• No unresolved bowel obstruction, uncontrolled gastrointestinal infection, chronic enteropathy (e.g., Crohn's disease or ulcerative colitis), or chronic diarrhea (= 4 stools per day) of any cause

• No recent history of seizures

• No clinical or radiological evidence of interstitial pneumonitis or pulmonary fibrosis,

• Capable of reliable oral self-medication

• No other condition that would make the patient unsuitable for participation in this study

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No major thoracic or abdominal surgery within the past 4 weeks

• No systemic anticancer therapy within the past 3 weeks

• No prior irinotecan hydrochloride

• No grapefruit juice within 3 days before and after each chemotherapy treatment

• No experimental drug therapy or antibody therapy, other than cetuximab, within the past 6 weeks

• No systemic chemotherapy and/or cetuximab within the past 3 weeks

• No antifungals or antibiotics within the past 5 days

• No ongoing requirement for cyclosporine or any other medication including, but not limited to, the following:

• Ketoconazole, fluconazole, itraconazole

• Erythromycin, clarithromycin, norfloxacin

• Diltiazem hydrochloride, verapamil, amiodarone hydrochloride

• Fluvoxamine

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Biological:
• panitumumab

Drug:
• cyclosporine

• irinotecan hydrochloride

Locations

Country	Name	City	State
United Kingdom	Ysbyty Gwynedd	Bangor	Wales
United Kingdom	Royal Bournemouth Hospital	Bournemouth	England
United Kingdom	Sussex Cancer Centre at Royal Sussex County Hospital	Brighton	England
United Kingdom	Bristol Haematology and Oncology Centre	Bristol	England
United Kingdom	Addenbrooke's Hospital	Cambridge	England
United Kingdom	Velindre Cancer Center at Velindre Hospital	Cardiff	Wales
United Kingdom	Gloucestershire Oncology Centre at Cheltenham General Hospital	Cheltenham	England
United Kingdom	Eastbourne District General Hospital	Eastbourne	England
United Kingdom	Edinburgh Cancer Centre at Western General Hospital	Edinburgh	Scotland
United Kingdom	St. Luke's Cancer Centre at Royal Surrey County Hospital	Guildford	England
United Kingdom	Huddersfield Royal Infirmary	Huddersfield, West Yorks	England
United Kingdom	Hinchingbrooke Hospital	Huntingdon	England
United Kingdom	Airedale General Hospital	Keighley	England
United Kingdom	Cookridge Hospital	Leeds	England
United Kingdom	Royal Liverpool University Hospital	Liverpool	England
United Kingdom	Queen Elizabeth Hospital - Woolwich	London	England
United Kingdom	St. Mary's Hospital	London	England
United Kingdom	UCL Cancer Institute	London	England
United Kingdom	Mid Kent Oncology Centre at Maidstone Hospital	Maidstone	England
United Kingdom	Clatterbridge Centre for Oncology	Merseyside	England
United Kingdom	James Cook University Hospital	Middlesbrough	England
United Kingdom	Mount Vernon Cancer Centre at Mount Vernon Hospital	Northwood	England
United Kingdom	Peterborough Hospitals Trust	Peterborough	England
United Kingdom	Dorset Cancer Centre	Poole Dorset	England
United Kingdom	Portsmouth Oncology Centre at Saint Mary's Hospital	Portsmouth Hants	England
United Kingdom	Glan Clwyd Hospital	Rhyl, Denbighshire	Wales
United Kingdom	Cancer Research Centre at Weston Park Hospital	Sheffield	England
United Kingdom	South Tyneside District Hospital	South Shields	England
United Kingdom	Royal Marsden - Surrey	Sutton	England
United Kingdom	South West Wales Cancer Institute	Swansea	Wales
United Kingdom	Great Western Hospital	Swindon	England
United Kingdom	Worthing Hospital	Worthing	England
United Kingdom	Yeovil District Hospital	Yeovil	England

Sponsors (1)

Lead Sponsor	Collaborator
University of Leeds

Country where clinical trial is conducted

United Kingdom, 

References & Publications (3)

Middleton G, Brown S, Lowe C, Maughan T, Gwyther S, Oliver A, Richman S, Blake D, Napp V, Marshall H, Wadsley J, Maisey N, Chau I, Hill M, Gollins S, Myint S, Slater S, Wagstaff J, Bridgewater J, Seymour M. A randomised phase III trial of the pharmacokine — View Citation

Seligmann JF, Elliott F, Richman SD, Jacobs B, Hemmings G, Brown S, Barrett JH, Tejpar S, Quirke P, Seymour MT. Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients — View Citation

Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P. Panitumumab and irinotecan vers — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients treated with irinotecan hydrochloride (Ir) alone vs Ir and cyclosporine (IrC) who are progression-free at 12 weeks
Primary	Overall survival of patients treated with Ir vs Ir and panitumumab (IrP) and no prior cetuximab
Secondary	Proportion of patients free from treatment failure at 12 weeks in patients treated with Ir vs IrC
Secondary	Overall survival in patients treated with Ir vs IrC
Secondary	Nurse-assessed toxicity (all-cause mortality, diarrhea = grade 3 at 12 weeks) in patients treated with Ir vs IrC
Secondary	Progression-free at 12 weeks in patients treated with Ir vs IrP and no prior cetuximab
Secondary	Nurse assessed toxicity (all-cause mortality) in patients treated with Ir vs IrP and no prior cetuximab
Secondary	Progression-free survival in patients treated with Ir vs IrP and prior cetuximab
Secondary	Best response at 1 year in patients treated with Ir vs IrP and prior cetuximab
Secondary	Patient-assessed symptom/quality of life/acceptability scores at 12 and 24 weeks in patients treated with Ir vs IrP and prior cetuximab